Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Cash & Equivalents (2022 - 2025)

Core Laboratories (CLB) has 4 years of Cash & Equivalents data on record, last reported at $25.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 19.35% year-over-year to $25.6 million; the TTM value through Sep 2025 reached $25.6 million, up 19.35%, while the annual FY2024 figure was $19.2 million, 26.7% up from the prior year.
  • Cash & Equivalents reached $25.6 million in Q3 2025 per CLB's latest filing, down from $31.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $31.2 million in Q2 2025 and bottomed at $14.9 million in Q1 2024.
  • Average Cash & Equivalents over 4 years is $20.5 million, with a median of $19.2 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: plummeted 32.47% in 2024, then skyrocketed 76.25% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $15.4 million in 2022, then decreased by 2.0% to $15.1 million in 2023, then grew by 26.7% to $19.2 million in 2024, then soared by 33.78% to $25.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $25.6 million in Q3 2025, $31.2 million in Q2 2025, and $22.1 million in Q1 2025.